WallStreetZenWallStreetZen

NASDAQ: ITCI
Intra Cellular Therapies Inc Stock

$67.30+0.30 (+0.45%)
Updated May 22, 2024
ITCI Price
$67.30
Fair Value Price
N/A
Market Cap
$7.11B
52 Week Low
$45.50
52 Week High
$84.89
P/E
-58.02x
P/B
11.85x
P/S
13.04x
PEG
N/A
Dividend Yield
N/A
Revenue
$513.93M
Earnings
-$110.87M
Gross Margin
92.8%
Operating Margin
-21.38%
Profit Margin
-21.6%
Debt to Equity
0.25
Operating Cash Flow
-$98M
Beta
0.91
Next Earnings
Jun 14, 2024
Ex-Dividend
N/A
Next Dividend
N/A

ITCI Overview

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Zen Score

Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ITCI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ITCI is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ITCI is poor value based on its book value relative to its share price (11.85x), compared to the US Drug Manufacturers - Specialty & Generic industry average (2.19x)
P/B vs Industry Valuation
ITCI is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ITCI due diligence checks available for Premium users.

Be the first to know about important ITCI news, forecast changes, insider trades & much more!

ITCI News

Valuation

ITCI fair value

Fair Value of ITCI stock based on Discounted Cash Flow (DCF)
Price
$67.30
Fair Value
-$1.61
Undervalued by
4,271.65%
ITCI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ITCI price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-58.02x
Industry
-1.12x
Market
31.29x

ITCI price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
11.85x
Industry
2.19x
ITCI is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ITCI's financial health

Profit margin

Revenue
$144.9M
Net Income
-$15.2M
Profit Margin
-10.5%
ITCI's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ITCI's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$747.0M
Liabilities
$147.5M
Debt to equity
0.25
ITCI's short-term assets ($690.53M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ITCI's short-term assets ($690.53M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ITCI's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ITCI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$34.1M
Investing
$16.2M
Financing
$10.0M
ITCI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ITCI vs Pharmaceutical Stocks

TickerMarket Cap1d %P/EP/B
ITCI$7.11B+0.45%-58.02x11.85x
ELAN$8.37B+1.38%-6.39x1.38x
LNTH$5.64B+0.80%12.07x5.96x
CTLT$9.95B+0.02%-8.47x2.76x
ALKS$4.10B-0.53%9.24x3.27x

Intra Cellular Therapies Stock FAQ

What is Intra Cellular Therapies's quote symbol?

(NASDAQ: ITCI) Intra Cellular Therapies trades on the NASDAQ under the ticker symbol ITCI. Intra Cellular Therapies stock quotes can also be displayed as NASDAQ: ITCI.

If you're new to stock investing, here's how to buy Intra Cellular Therapies stock.

What is the 52 week high and low for Intra Cellular Therapies (NASDAQ: ITCI)?

(NASDAQ: ITCI) Intra Cellular Therapies's 52-week high was $84.89, and its 52-week low was $45.50. It is currently -20.72% from its 52-week high and 47.91% from its 52-week low.

How much is Intra Cellular Therapies stock worth today?

(NASDAQ: ITCI) Intra Cellular Therapies currently has 105,574,855 outstanding shares. With Intra Cellular Therapies stock trading at $67.30 per share, the total value of Intra Cellular Therapies stock (market capitalization) is $7.11B.

Intra Cellular Therapies stock was originally listed at a price of $15.00 in Jan 7, 2014. If you had invested in Intra Cellular Therapies stock at $15.00, your return over the last 10 years would have been 348.67%, for an annualized return of 16.2% (not including any dividends or dividend reinvestments).

How much is Intra Cellular Therapies's stock price per share?

(NASDAQ: ITCI) Intra Cellular Therapies stock price per share is $67.30 today (as of May 22, 2024).

What is Intra Cellular Therapies's Market Cap?

(NASDAQ: ITCI) Intra Cellular Therapies's market cap is $7.11B, as of May 23, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Intra Cellular Therapies's market cap is calculated by multiplying ITCI's current stock price of $67.30 by ITCI's total outstanding shares of 105,574,855.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.